These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 35577663

  • 21. Fentanyl Test Strips for Harm Reduction: A Scoping Review.
    Kutscher E, Barber Grossi M, LaPolla F, Lee JD.
    J Addict Med; ; 18(4):373-380. PubMed ID: 38829042
    [Abstract] [Full Text] [Related]

  • 22. Differences in drug use behaviors that impact overdose risk among individuals who do and do not use fentanyl test strips for drug checking.
    Tilhou AS, Zaborek J, Baltes A, Salisbury-Afshar E, Malicki J, Brown R.
    Harm Reduct J; 2023 Mar 28; 20(1):41. PubMed ID: 36978170
    [Abstract] [Full Text] [Related]

  • 23. A pilot study assessing client understanding and use of fentanyl test strips for harm reduction.
    Barrolle AA, Gable KN, Dell N.
    J Am Pharm Assoc (2003); 2023 Mar 28; 63(1):295-300. PubMed ID: 36280433
    [Abstract] [Full Text] [Related]

  • 24. High willingness to use rapid fentanyl test strips among young adults who use drugs.
    Krieger MS, Yedinak JL, Buxton JA, Lysyshyn M, Bernstein E, Rich JD, Green TC, Hadland SE, Marshall BDL.
    Harm Reduct J; 2018 Feb 08; 15(1):7. PubMed ID: 29422052
    [Abstract] [Full Text] [Related]

  • 25. "It wasn't here, and now it is. It's everywhere": fentanyl's rising presence in Oregon's drug supply.
    Shin SS, LaForge K, Stack E, Pope J, Leichtling G, Larsen JE, Leahy JM, Seaman A, Hoover D, Chisholm L, Blazes C, Baker R, Byers M, Branson K, Korthuis PT.
    Harm Reduct J; 2022 Jul 11; 19(1):76. PubMed ID: 35818072
    [Abstract] [Full Text] [Related]

  • 26. Association of Fentanyl Test Strip Use, Perceived Overdose Risk, and Naloxone Possession among People Who Use Drugs.
    Tilhou AS, Zaborek J, Baltes A, Salisbury-Afshar E, Malicki J, Brown R.
    Subst Use Misuse; 2024 Jul 11; 59(2):254-257. PubMed ID: 37807227
    [Abstract] [Full Text] [Related]

  • 27. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study.
    Carroll JJ, Marshall BDL, Rich JD, Green TC.
    Int J Drug Policy; 2017 Aug 11; 46():136-145. PubMed ID: 28578864
    [Abstract] [Full Text] [Related]

  • 28. Strategies used to reduce harms associated with fentanyl exposure among rural people who use drugs: multi-site qualitative findings from the rural opioid initiative.
    Walters SM, Baker R, Frank D, Fadanelli M, Rudolph AE, Zule W, Fredericksen RJ, Bolinski R, Sibley AL, Go VF, Ouellet LJ, Pho MT, Seal DW, Feinberg J, Smith G, Young AM, Stopka TJ.
    Harm Reduct J; 2024 Aug 24; 21(1):154. PubMed ID: 39182116
    [Abstract] [Full Text] [Related]

  • 29. Prevalence and correlates of fentanyl test strip use among people who use drugs in Rhode Island.
    Goldman JE, Park CJ, Trombley J, Park JN, Buxton JA, Hadland SE, Macmadu A, Marshall BD.
    Drug Alcohol Depend; 2024 Nov 01; 264():112446. PubMed ID: 39305808
    [Abstract] [Full Text] [Related]

  • 30. Expanding harm reduction to include fentanyl urine testing: results from a pilot in rural British Columbia.
    Mema SC, Sage C, Popoff S, Bridgeman J, Taylor D, Corneil T.
    Harm Reduct J; 2018 Apr 06; 15(1):19. PubMed ID: 29625621
    [Abstract] [Full Text] [Related]

  • 31. Investigating opioid preference to inform safe supply services: A cross sectional study.
    Ferguson M, Parmar A, Papamihali K, Weng A, Lock K, Buxton JA.
    Int J Drug Policy; 2022 Mar 06; 101():103574. PubMed ID: 35007878
    [Abstract] [Full Text] [Related]

  • 32. Correlates of fentanyl preference among people who use drugs in Rhode Island.
    Napoleon SC, Park CJ, Goldman J, Li Y, Buxton JA, Macmadu A, Biello KB, Noguchi J, Marshall BDL.
    Harm Reduct J; 2024 Sep 14; 21(1):169. PubMed ID: 39272059
    [Abstract] [Full Text] [Related]

  • 33. Stakeholder perspectives on implementing fentanyl drug checking: Results from a multi-site study.
    Glick JL, Christensen T, Park JN, McKenzie M, Green TC, Sherman SG.
    Drug Alcohol Depend; 2019 Jan 01; 194():527-532. PubMed ID: 30551090
    [Abstract] [Full Text] [Related]

  • 34. Community partner perspectives on the implementation of a novel safer supply program in Canada: a qualitative study of the MySafe Project.
    Mansoor M, Foreman-Mackey A, Ivsins A, Bardwell G.
    Harm Reduct J; 2023 Apr 28; 20(1):61. PubMed ID: 37118799
    [Abstract] [Full Text] [Related]

  • 35. A mixed-methods analysis of risk-reduction strategies adopted by syringe services program participants and non-syringe services program participants in New York City.
    Beharie N, Urmanche A, Harocopos A.
    Harm Reduct J; 2023 Mar 25; 20(1):38. PubMed ID: 36966342
    [Abstract] [Full Text] [Related]

  • 36. Perspectives of people in Philadelphia who use fentanyl/heroin adulterated with the animal tranquilizer xylazine; Making a case for xylazine test strips.
    Reed MK, Imperato NS, Bowles JM, Salcedo VJ, Guth A, Rising KL.
    Drug Alcohol Depend Rep; 2022 Sep 25; 4():100074. PubMed ID: 36846574
    [Abstract] [Full Text] [Related]

  • 37. Agency in the fentanyl era: Exploring the utility of fentanyl test strips in an opaque drug market.
    Weicker NP, Owczarzak J, Urquhart G, Park JN, Rouhani S, Ling R, Morris M, Sherman SG.
    Int J Drug Policy; 2020 Oct 25; 84():102900. PubMed ID: 32769054
    [Abstract] [Full Text] [Related]

  • 38. Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont.
    Erath TG, LaCroix R, O'Keefe E, Higgins ST, Rawson RA.
    Harm Reduct J; 2024 Apr 05; 21(1):76. PubMed ID: 38580997
    [Abstract] [Full Text] [Related]

  • 39. Monitoring for fentanyl within Australian supervised injecting facilities: Findings from feasibility testing of novel methods and collaborative workshops.
    Nielsen S, Barratt M, Hiley S, Bartlett M, Latimer J, Jauncey M, Roux C, Morelato M, Clark N, Kowalski M, Gilbert M, Francia L, Shipton A, Gerostamoulos D, Glowacki L, Lam T.
    Int J Drug Policy; 2023 May 05; 115():104015. PubMed ID: 37043848
    [Abstract] [Full Text] [Related]

  • 40. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence.
    Sherman SG, Morales KB, Park JN, McKenzie M, Marshall BDL, Green TC.
    Int J Drug Policy; 2019 Jun 05; 68():46-53. PubMed ID: 30991301
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.